Lantheus Holdings (LNTH) has drawn fresh attention after recent share price moves, with the stock closing at $109.80. Investors are reassessing what the company’s diagnostics and radiopharmaceutical portfolio implies for current valuation.

The recent move in Lantheus Holdings fits into a strong run, with a 30 day share price return of 10.57% and year to date share price return of 63.22%, while the 5 year total shareholder return of 285.13% points to momentum that has been building over a longer horizon.

If you like what is happening with Lantheus Holdings and want to see more opportunities in healthcare related technology, this is a good moment to review 39 healthcare AI stocks

With Lantheus Holdings trading around $109.80 and an indicated 44% intrinsic discount, investors are left with a core question: is the stock still undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 5.5% Overvalued

At $109.80, Lantheus Holdings sits modestly above the most widely followed fair value estimate of $104.08, which is built on detailed long term forecasts and a 7.74% discount rate.

Multiple new product launches within the next 18 months including the new F-18 PSMA PET, MK-6240, OCTEVY, and PNT2003 are set to diversify the revenue base, mitigate concentration risk, and open additional growth channels in oncology and neuroendocrine tumor imaging, supporting both top-line and future earnings expansion.

Curious what kind of revenue mix, margin profile, and earnings power those launches would need to support this valuation? The narrative leans on a specific growth curve, a richer profit margin profile, and a future earnings multiple that assumes investors stay comfortable paying up for Lantheus Holdings.

Result: Fair Value of $104.08 (OVERVALUED)

However, this hinges on Lantheus Holdings managing rising PSMA PET price competition and reducing its heavy reliance on PYLARIFY, where reimbursement or share losses could pressure the story.

Another View on Lantheus Holdings Using Market Ratios

While the analyst narrative sees Lantheus Holdings as about 5.5% overvalued against a $104.08 fair value, the market ratios tell a more balanced story. The P/E of 25.6x is slightly higher than the company’s own fair ratio of 25.5x, yet sits below the US Medical Equipment industry at 26.2x and well below peer averages at 38.8x. That combination points to limited multiple upside if sentiment cools, but also suggests the stock is not priced at the top of its group. This raises the question: which signal do you trust more right now?

To see how this pricing gap stacks up against the underlying numbers, take a closer look at the full valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mix of optimism and concern around Lantheus Holdings feels finely balanced, treat this as a prompt to review the key numbers and come to your own judgment using the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Lantheus Holdings?

If you are serious about sharpening your portfolio alongside Lantheus Holdings, use the Simply Wall St screener to uncover fresh opportunities before other investors focus on them.

• Spot potential upside early by checking out screener containing 19 high quality undiscovered gems that combine quality fundamentals with lower market attention.
• Strengthen your portfolio core by using the solid balance sheet and fundamentals stocks screener (48 results) to find companies with resilient finances and solid underlying business profiles.
• Protect against sleepless nights by filtering for 71 resilient stocks with low risk scores that score well on stability and business quality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.